It’s the very thing patients need to hear as Christmas time approaches; more developments were published today on the fight against cancer.
Ottawa-based Tetra Bio-Pharma Inc. (TSX-Venture:TBP) is trumpeting its status as a leader in cannabinoid-derived drug discovery and development. Tuesday, it announced it will be requesting a meeting with the U.S. Food and Drug Administration (FDA) to discuss the drug development program for its Orphan Drug candidate HCC011, inhaled delta-9-tetrahydrocannabinol (THC), in the treatment of hepatocellular carcinoma.
Hepatocellular carcinoma (HCC), also known as primary liver cancer, is the most common form of liver cancer and is responsible for 80% of the primary malignant liver tumors in adults. In addition to quality of life benefits to cancer patients, based on preclinical research, HCC011 should also have anti-tumor effects.
Tuesday’s news release indicated the Phase 2 study of HCC011 will target patients with disease progression on Sorafenib, have measurable disease, and Child-Pugh Class A liver impairment.
The Phase 2 trial will consist of a single arm. Patients will receive the HCC011 by inhalation three times daily, in combination with Sorafenib, until disease progression or unacceptable toxicity.
Shares in TBP gained 2.5 cents, or 5.4%, to 48.5 cents, on volume of 434,000
